Nyvatex Health-Mat(TM) Shown to Stimulate T-Cell Proliferation
BILLINGS, Mont., Sept. 21 /PRNewswire-FirstCall/ -- Nyvatex (OTC: NYVA) announced today that an in vitro test of its patented Nyvalon(TM) Health-Mat(TM) at a prominent Midwestern university showed a statistically significant 55% improvement in T-cell proliferation in blood samples placed with Nyvalon(TM) versus the control. Blood from 12 volunteers over 65 years of age was tested by incubation in cultured media with and without PHA (which activates T-cells). Nyvalon(TM)'s effect on T-cells treated with PHA was not statistically significant, but T-cells in culture media alone without PHA treatment proliferated to a statistically significant value of 0.547 when exposed to Nyvalon(TM), compared to 0.353 when not exposed to Nyvalon(TM). Nyvatex CEO John C. Ledbetter stated that the improvement in non-PHA-treated T-cells suggests that Nyvalon(TM) is encouraging proliferation of naive T-cells. Describing the potential significance of the test results, Ledbetter stated: "These results may offer an explanation for the substantial immune system benefits reported over many years by users of the Nyvatex Health-Mat(TM). We have seen that people who sleep on the Health-Mat(TM) do not suffer the annual cough-cold-flu syndrome experienced by most of the U.S. population." About Nyvalon(TM) Nyvalon(TM) is the non-magnetic material inside the Nyvatex Health-Mat and other Nyvatex health products that have been available for purchase from Nyvatex since 1975 and have been used by thousands of individuals. The material was developed at Nyvatex to assist in countering the negative effects of living, working and traveling in Faraday cages, which insulate people from the beneficial effects of exposure to the earth's natural fields. About Nyvatex Nyvatex Health Products is a wholly-owned subsidiary of Nyvatex Oil Corp., an oil exploration company dedicated to the development of technologies premised on naturally occurring geophysical phenomena. Nyvatex was founded in 1968. Forward-Looking Statements This press release contains forward-looking statements relating to expectations, plans or prospects for Nyvatex, including its ability to expand market awareness of Nyvalon(TM)-based products, its ability to further the scientific rationale for the benefits of such products and its ability to distribute these products to a broad segment of the population. These possibilities are subject to numerous risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further information: Tel (406) 252-3429 Fax (406) 252-6440 www.nyvatex.com e-mail: firstname.lastname@example.org John C. Ledbetter, CEO Nyvatex, 3021 6th Avenue North, P.O. Box 1835, Billings, Montana 59103
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.